Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 57

1.

Antigenic expression and spontaneous immune responses support the use of a selected peptide set from the IMA950 glioblastoma vaccine for immunotherapy of grade II and III glioma.

Dutoit V, Migliorini D, Ranzanici G, Marinari E, Widmer V, Lobrinus JA, Momjian S, Costello J, Walker PR, Okada H, Weinschenk T, Herold-Mende C, Dietrich PY.

Oncoimmunology. 2017 Nov 7;7(2):e1391972. doi: 10.1080/2162402X.2017.1391972. eCollection 2018.

2.

Glut3 Addiction Is a Druggable Vulnerability for a Molecularly Defined Subpopulation of Glioblastoma.

Cosset É, Ilmjärv S, Dutoit V, Elliott K, von Schalscha T, Camargo MF, Reiss A, Moroishi T, Seguin L, Gomez G, Moo JS, Preynat-Seauve O, Krause KH, Chneiweiss H, Sarkaria JN, Guan KL, Dietrich PY, Weis SM, Mischel PS, Cheresh DA.

Cancer Cell. 2017 Dec 11;32(6):856-868.e5. doi: 10.1016/j.ccell.2017.10.016. Epub 2017 Nov 30.

PMID:
29198914
3.

First report of clinical responses to immunotherapy in 3 relapsing cases of chordoma after failure of standard therapies.

Migliorini D, Mach N, Aguiar D, Vernet R, Landis BN, Becker M, McKee T, Dutoit V, Dietrich PY.

Oncoimmunology. 2017 Jun 21;6(8):e1338235. doi: 10.1080/2162402X.2017.1338235. eCollection 2017.

4.

[Brain tumor immunotherapy: Illusion or hope?]

Migliorini D, Dutoit V, Walker PR, Dietrich PY.

Bull Cancer. 2017 May;104(5):476-484. doi: 10.1016/j.bulcan.2017.01.014. Epub 2017 Mar 17. Review. French.

PMID:
28318492
5.

ER-mitochondria contacts control surface glycan expression and sensitivity to killer lymphocytes in glioma stem-like cells.

Bassoy EY, Kasahara A, Chiusolo V, Jacquemin G, Boydell E, Zamorano S, Riccadonna C, Pellegatta S, Hulo N, Dutoit V, Derouazi M, Dietrich PY, Walker PR, Martinvalet D.

EMBO J. 2017 Jun 1;36(11):1493-1512. doi: 10.15252/embj.201695429. Epub 2017 Mar 10.

6.

Immunotherapy of Malignant Tumors in the Brain: How Different from Other Sites?

Dutoit V, Migliorini D, Dietrich PY, Walker PR.

Front Oncol. 2016 Dec 7;6:256. doi: 10.3389/fonc.2016.00256. eCollection 2016. Review.

7.

Human tissue engineering allows the identification of active miRNA regulators of glioblastoma aggressiveness.

Cosset E, Petty T, Dutoit V, Tirefort D, Otten-Hernandez P, Farinelli L, Dietrich PY, Preynat-Seauve O.

Biomaterials. 2016 Nov;107:74-87. doi: 10.1016/j.biomaterials.2016.08.009. Epub 2016 Aug 24.

PMID:
27614160
8.

Ipilimumab-related hypophysitis may precede severe CNS immune attack.

Köessler T, Olivier T, Fertani S, Marinari E, Dutoit V, Dietrich PY.

Ann Oncol. 2016 Oct;27(10):1975-6. doi: 10.1093/annonc/mdw255. Epub 2016 Jun 29. No abstract available.

PMID:
27358386
9.

Immunotherapy of Brain Tumors.

Dutoit V, Migliorini D, Walker PR, Dietrich PY.

Prog Tumor Res. 2015;42:11-21. doi: 10.1159/000436986. Epub 2015 Sep 4. Review.

PMID:
26376741
10.

Extrachromosomal driver mutations in glioblastoma and low-grade glioma.

Nikolaev S, Santoni F, Garieri M, Makrythanasis P, Falconnet E, Guipponi M, Vannier A, Radovanovic I, Bena F, Forestier F, Schaller K, Dutoit V, Clement-Schatlo V, Dietrich PY, Antonarakis SE.

Nat Commun. 2014 Dec 4;5:5690. doi: 10.1038/ncomms6690.

11.

Immunotherapy for glioma: from illusion to realistic prospects?

Dietrich PY, Dutoit V, Walker PR.

Am Soc Clin Oncol Educ Book. 2014:51-9. doi: 10.14694/EdBook_AM.2014.34.51. Review.

12.

Comprehensive metagenomic analysis of glioblastoma reveals absence of known virus despite antiviral-like type I interferon gene response.

Cosset É, Petty TJ, Dutoit V, Cordey S, Padioleau I, Otten-Hernandez P, Farinelli L, Kaiser L, Bruyère-Cerdan P, Tirefort D, Amar El-Dusouqui S, Nayernia Z, Krause KH, Zdobnov EM, Dietrich PY, Rigal E, Preynat-Seauve O.

Int J Cancer. 2014 Sep 15;135(6):1381-9. doi: 10.1002/ijc.28670. Epub 2014 May 8.

13.

The relationship between brain tumor cell invasion of engineered neural tissues and in vivo features of glioblastoma.

Nayernia Z, Turchi L, Cosset E, Peterson H, Dutoit V, Dietrich PY, Tirefort D, Chneiweiss H, Lobrinus JA, Krause KH, Virolle T, Preynat-Seauve O.

Biomaterials. 2013 Nov;34(33):8279-90. doi: 10.1016/j.biomaterials.2013.07.006. Epub 2013 Jul 27.

PMID:
23899445
14.

Phase 2 trial of single-agent everolimus in chemotherapy-naive patients with castration-resistant prostate cancer (SAKK 08/08).

Templeton AJ, Dutoit V, Cathomas R, Rothermundt C, Bärtschi D, Dröge C, Gautschi O, Borner M, Fechter E, Stenner F, Winterhalder R, Müller B, Schiess R, Wild PJ, Rüschoff JH, Thalmann G, Dietrich PY, Aebersold R, Klingbiel D, Gillessen S; Swiss Group for Clinical Cancer Research (SAKK).

Eur Urol. 2013 Jul;64(1):150-8. doi: 10.1016/j.eururo.2013.03.040. Epub 2013 Apr 6.

PMID:
23582881
15.

Exploiting the glioblastoma peptidome to discover novel tumour-associated antigens for immunotherapy.

Dutoit V, Herold-Mende C, Hilf N, Schoor O, Beckhove P, Bucher J, Dorsch K, Flohr S, Fritsche J, Lewandrowski P, Lohr J, Rammensee HG, Stevanovic S, Trautwein C, Vass V, Walter S, Walker PR, Weinschenk T, Singh-Jasuja H, Dietrich PY.

Brain. 2012 Apr;135(Pt 4):1042-54. doi: 10.1093/brain/aws042. Epub 2012 Mar 14.

PMID:
22418738
16.

A novel function of junctional adhesion molecule-C in mediating melanoma cell metastasis.

Langer HF, Orlova VV, Xie C, Kaul S, Schneider D, Lonsdorf AS, Fahrleitner M, Choi EY, Dutoit V, Pellegrini M, Grossklaus S, Nawroth PP, Baretton G, Santoso S, Hwang ST, Arnold B, Chavakis T.

Cancer Res. 2011 Jun 15;71(12):4096-105. doi: 10.1158/0008-5472.CAN-10-2794. Epub 2011 May 18.

17.

T-cell immunotherapy for malignant glioma: toward a combined approach.

Dietrich PY, Dutoit V, Tran Thang NN, Walker PR.

Curr Opin Oncol. 2010 Nov;22(6):604-10. doi: 10.1097/CCO.0b013e32833dead8. Review.

PMID:
20739889
18.

Treatment of hepatitis C in HCV mono-infected and in HIV-HCV co-infected patients: an open-labelled comparison study.

Gonvers JJ, Heim MH, Cavassini M, Müllhaupt B, Genné D, Bernasconi E, Borovicka J, Cerny A, Chave JP, Chuard C, Dufour F, Dutoit V, Malinverni R, Monnat M, Negro F, Troilliet N, Oneta C.

Swiss Med Wkly. 2010 Jul 19;140:w13055. doi: 10.4414/smw.2010.13055.

PMID:
20648398
19.

Limits of CD133 as a marker of glioma self-renewing cells.

Clément V, Dutoit V, Marino D, Dietrich PY, Radovanovic I.

Int J Cancer. 2009 Jul 1;125(1):244-8. doi: 10.1002/ijc.24352.

20.

Polyfunctional HCV-specific T-cell responses are associated with effective control of HCV replication.

Ciuffreda D, Comte D, Cavassini M, Giostra E, Bühler L, Perruchoud M, Heim MH, Battegay M, Genné D, Mulhaupt B, Malinverni R, Oneta C, Bernasconi E, Monnat M, Cerny A, Chuard C, Borovicka J, Mentha G, Pascual M, Gonvers JJ, Pantaleo G, Dutoit V.

Eur J Immunol. 2008 Oct;38(10):2665-77. doi: 10.1002/eji.200838336.

21.

Effect of synthetic agonists of toll-like receptor 9 on canine lymphocyte proliferation and cytokine production in vitro.

Im Hof M, Williamson L, Summerfield A, Balmer V, Dutoit V, Kandimalla ER, Yu D, Zurbriggen A, Doherr MG, Peel J, Roosje PJ.

Vet Immunol Immunopathol. 2008 Jul 15;124(1-2):120-31. doi: 10.1016/j.vetimm.2008.03.002. Epub 2008 Mar 20.

PMID:
18452997
22.

Changes in self-reactive IgG antibody repertoire after treatment of experimental autoimmune encephalomyelitis with anti-allergic drugs.

El Behi M, Zéphir H, Lefranc D, Dutoit V, Dussart P, Devos P, Dessaint JP, Vermersch P, Prin L.

J Neuroimmunol. 2007 Jan;182(1-2):80-8. Epub 2006 Nov 13.

PMID:
17097744
23.

Tissue homing and persistence of defined antigen-specific CD8+ tumor-reactive T-cell clones in long-term melanoma survivors.

Le Gal FA, Widmer VM, Dutoit V, Rubio-Godoy V, Schrenzel J, Walker PR, Romero PJ, Valmori D, Speiser DE, Dietrich PY.

J Invest Dermatol. 2007 Mar;127(3):622-9. Epub 2006 Oct 12.

24.

Sharing skills in Indigenous communities.

Lurie S, Lurie R, DuToit V.

Aust Nurs J. 2006 Aug;14(2):29. No abstract available.

PMID:
16925053
25.

Functional signatures of protective antiviral T-cell immunity in human virus infections.

Harari A, Dutoit V, Cellerai C, Bart PA, Du Pasquier RA, Pantaleo G.

Immunol Rev. 2006 Jun;211:236-54. Review.

PMID:
16824132
26.

Differences in HCV-specific T cell responses between chronic HCV infection and HIV/HCV co-infection.

Dutoit V, Ciuffreda D, Comte D, Gonvers JJ, Pantaleo G.

Eur J Immunol. 2005 Dec;35(12):3493-504.

27.

Distinct structural TCR repertoires in naturally occurring versus vaccine-induced CD8+ T-cell responses to the tumor-specific antigen NY-ESO-1.

Le Gal FA, Ayyoub M, Dutoit V, Widmer V, Jäger E, Cerottini JC, Dietrich PY, Valmori D.

J Immunother. 2005 May-Jun;28(3):252-7.

PMID:
15838382
28.

Lentivirus-mediated RNA interference of DC-SIGN expression inhibits human immunodeficiency virus transmission from dendritic cells to T cells.

Arrighi JF, Pion M, Wiznerowicz M, Geijtenbeek TB, Garcia E, Abraham S, Leuba F, Dutoit V, Ducrey-Rundquist O, van Kooyk Y, Trono D, Piguet V.

J Virol. 2004 Oct;78(20):10848-55.

29.

Evaluation of anti-citrullinated filaggrin antibodies as hallmarks for the diagnosis of rheumatic diseases.

Dubucquoi S, Solau-Gervais E, Lefranc D, Marguerie L, Sibilia J, Goetz J, Dutoit V, Fauchais AL, Hachulla E, Flipo RM, Prin L.

Ann Rheum Dis. 2004 Apr;63(4):415-9.

30.

Simultaneous CD8+ T cell responses to multiple tumor antigen epitopes in a multipeptide melanoma vaccine.

Valmori D, Dutoit V, Ayyoub M, Rimoldi D, Guillaume P, Liénard D, Lejeune F, Cerottini JC, Romero P, Speiser DE.

Cancer Immun. 2003 Oct 28;3:15.

31.

SSX antigens as tumor vaccine targets in human sarcoma.

Ayyoub M, Brehm M, Metthez G, Talbot S, Dutoit V, Taub RN, Keohan ML, Gure AO, Chen YT, Williamson B, Jungbluth AA, Old LJ, Hesdorffer CS, Valmori D.

Cancer Immun. 2003 Oct 9;3:13.

32.
33.
34.

Prevalent role of TCR alpha-chain in the selection of the preimmune repertoire specific for a human tumor-associated self-antigen.

Dietrich PY, Le Gal FA, Dutoit V, Pittet MJ, Trautman L, Zippelius A, Cognet I, Widmer V, Walker PR, Michielin O, Guillaume P, Connerotte T, Jotereau F, Coulie PG, Romero P, Cerottini JC, Bonneville M, Valmori D.

J Immunol. 2003 May 15;170(10):5103-9.

36.

Multiepitope CD8(+) T cell response to a NY-ESO-1 peptide vaccine results in imprecise tumor targeting.

Dutoit V, Taub RN, Papadopoulos KP, Talbot S, Keohan ML, Brehm M, Gnjatic S, Harris PE, Bisikirska B, Guillaume P, Cerottini JC, Hesdorffer CS, Old LJ, Valmori D.

J Clin Invest. 2002 Dec;110(12):1813-22.

37.

Therapeutic cancer vaccines based on molecularly defined human tumor antigens.

Romero P, Pittet M, Dutoit V, Zippelius A, Liénard D, Lejeune F, Guillaume P, Rimoldi D, Valmori D, Speiser DE, Cerottini JC.

Vaccine. 2002 Dec 19;20 Suppl 4:A2-7.

PMID:
12477422
38.

Antigenicity and immunogenicity of Melan-A/MART-1 derived peptides as targets for tumor reactive CTL in human melanoma.

Romero P, Valmori D, Pittet MJ, Zippelius A, Rimoldi D, Lévy F, Dutoit V, Ayyoub M, Rubio-Godoy V, Michielin O, Guillaume P, Batard P, Luescher IF, Lejeune F, Liénard D, Rufer N, Dietrich PY, Speiser DE, Cerottini JC.

Immunol Rev. 2002 Oct;188:81-96. Review.

PMID:
12445283
39.

Positional scanning-synthetic peptide library-based analysis of self- and pathogen-derived peptide cross-reactivity with tumor-reactive Melan-A-specific CTL.

Rubio-Godoy V, Dutoit V, Zhao Y, Simon R, Guillaume P, Houghten R, Romero P, Cerottini JC, Pinilla C, Valmori D.

J Immunol. 2002 Nov 15;169(10):5696-707.

40.

Combinatorial peptide library-based identification of peptide ligands for tumor-reactive cytolytic T lymphocytes of unknown specificity.

Rubio-Godoy V, Ayyoub M, Dutoit V, Servis C, Schink A, Rimoldi D, Romero P, Cerottini JC, Simon R, Zhao Y, Houghten RA, Pinilla C, Valmori D.

Eur J Immunol. 2002 Aug;32(8):2292-9.

41.

Interferon beta in multiple sclerosis: relationship between sustained serum IgG levels and clinical outcome.

Dubucquoi S, de Seze J, Lefranc D, Almeras L, Dutoit V, Prin L, Vermersch P.

J Neuroimmunol. 2002 Aug;129(1-2):232.

PMID:
12161040
42.

Degeneracy of antigen recognition as the molecular basis for the high frequency of naive A2/Melan-a peptide multimer(+) CD8(+) T cells in humans.

Dutoit V, Rubio-Godoy V, Pittet MJ, Zippelius A, Dietrich PY, Legal FA, Guillaume P, Romero P, Cerottini JC, Houghten RA, Pinilla C, Valmori D.

J Exp Med. 2002 Jul 15;196(2):207-16.

43.

Vaccination with a Melan-A peptide selects an oligoclonal T cell population with increased functional avidity and tumor reactivity.

Valmori D, Dutoit V, Schnuriger V, Quiquerez AL, Pittet MJ, Guillaume P, Rubio-Godoy V, Walker PR, Rimoldi D, Liénard D, Cerottini JC, Romero P, Dietrich PY.

J Immunol. 2002 Apr 15;168(8):4231-40.

45.

Circulating Tumor-reactive CD8(+) T cells in melanoma patients contain a CD45RA(+)CCR7(-) effector subset exerting ex vivo tumor-specific cytolytic activity.

Valmori D, Scheibenbogen C, Dutoit V, Nagorsen D, Asemissen AM, Rubio-Godoy V, Rimoldi D, Guillaume P, Romero P, Schadendorf D, Lipp M, Dietrich PY, Thiel E, Cerottini JC, Liénard D, Keilholz U.

Cancer Res. 2002 Mar 15;62(6):1743-50.

46.

Functional avidity of tumor antigen-specific CTL recognition directly correlates with the stability of MHC/peptide multimer binding to TCR.

Dutoit V, Rubio-Godoy V, Doucey MA, Batard P, Liénard D, Rimoldi D, Speiser D, Guillaume P, Cerottini JC, Romero P, Valmori D.

J Immunol. 2002 Feb 1;168(3):1167-71.

47.

Discrepancy between ELISPOT IFN-gamma secretion and binding of A2/peptide multimers to TCR reveals interclonal dissociation of CTL effector function from TCR-peptide/MHC complexes half-life.

Rubio-Godoy V, Dutoit V, Rimoldi D, Lienard D, Lejeune F, Speiser D, Guillaume P, Cerottini JC, Romero P, Valmori D.

Proc Natl Acad Sci U S A. 2001 Aug 28;98(18):10302-7. Epub 2001 Aug 21.

48.

Heterogeneous T-cell response to MAGE-A10(254-262): high avidity-specific cytolytic T lymphocytes show superior antitumor activity.

Dutoit V, Rubio-Godoy V, Dietrich PY, Quiqueres AL, Schnuriger V, Rimoldi D, Liénard D, Speiser D, Guillaume P, Batard P, Cerottini JC, Romero P, Valmori D.

Cancer Res. 2001 Aug 1;61(15):5850-6.

49.

Combinatorial peptide libraries as an alternative approach to the identification of ligands for tumor-reactive cytolytic T lymphocytes.

Pinilla C, Rubio-Godoy V, Dutoit V, Guillaume P, Simon R, Zhao Y, Houghten RA, Cerottini JC, Romero P, Valmori D.

Cancer Res. 2001 Jul 1;61(13):5153-60.

50.

IgG reactivity against citrullinated myelin basic protein in multiple sclerosis.

de Seze J, Dubucquoi S, Lefranc D, Virecoulon F, Nuez I, Dutoit V, Vermersch P, Prin L.

J Neuroimmunol. 2001 Jul 2;117(1-2):149-55.

PMID:
11431015

Supplemental Content

Loading ...
Support Center